Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-12-30 Sale |
2025-01-02 4:15 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
29,846 | $25.54 | $762,174 | 10,656,172 (Indirect) |
View |
| 2024-12-26 Sale |
2024-12-30 4:15 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
74,910 | $25.98 | $1,945,918 | 10,686,018 (Indirect) |
View |
| 2024-12-20 Sale |
2024-12-26 4:15 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
91,068 | $25.58 | $2,329,520 | 10,760,928 (Indirect) |
View |
| 2024-12-18 Sale |
2024-12-20 4:25 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
157,234 | $25.86 | $4,066,714 | 10,851,996 (Indirect) |
View |
| 2024-12-16 Sale |
2024-12-18 4:15 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
115,480 | $25.95 | $2,996,156 | 11,009,230 (Indirect) |
View |
| 2024-12-12 Sale |
2024-12-16 4:15 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
191,762 | $25.34 | $4,859,875 | 11,124,710 (Indirect) |
View |
| 2024-12-10 Sale |
2024-12-12 4:15 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
462,288 | $25.4 | $11,740,618 | 11,316,472 (Indirect) |
View |
| 2024-11-15 Sale |
2024-11-19 4:15 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
41,803 | $25.07 | $1,047,876 | 11,778,760 (Indirect) |
View |
| 2024-11-13 Sale |
2024-11-15 4:36 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
10,898 | $25.01 | $272,511 | 11,820,563 (Indirect) |
View |
| 2024-10-01 Sale |
2024-10-01 5:23 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer |
45,000 | $15.72 | $707,400 | 168,073 (Direct) |
View |
| 2024-09-26 Purchase |
2024-09-30 5:22 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Audet Juliette Berangere Chief Business Officer |
1,104 | $15.7 | $17,333 | 1,104 (Direct) |
View |
| 2024-08-20 Purchase |
2024-08-22 4:30 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer |
5,000 | $16.27 | $81,350 | 818,563 (Indirect Direct) |
View |
| 2024-06-20 Purchase |
2024-06-24 08:30 am |
NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer |
5,000 | $17.26 | $86,309 | 813,563 (Indirect Direct) |
View |
| 2024-03-26 Purchase |
2024-03-28 4:30 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director |
8,429 | $21.5 | $181,224 | 6,809,429 (Indirect) |
View |
| 2024-03-26 Sale |
2024-03-27 4:30 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer |
190,476 | $21.5 | $4,095,234 | 970,229 (Indirect) |
View |
| 2024-02-13 Purchase |
2024-02-21 5:00 pm |
NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director |
5,000 | $19 | $95,000 | 24,878 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-01-02 Option Award |
2025-01-06 5:57 pm |
N/A 2035-01-02 |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
250,000 | $0 | 250,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 5:56 pm |
N/A 2035-01-02 |
NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer |
80,000 | $0 | 80,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 5:54 pm |
N/A 2035-01-02 |
NewAmsterdam Pharma Co N.V. | NAMS | Audet Juliette Berangere Chief Business Officer |
100,000 | $0 | 100,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 5:53 pm |
N/A 2035-01-02 |
NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer |
220,000 | $0 | 220,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 5:51 pm |
N/A 2035-01-02 |
NewAmsterdam Pharma Co N.V. | NAMS | JONES WILLIAM A JR Chief Commercial Officer |
200,000 | $0 | 200,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 5:48 pm |
N/A 2035-01-02 |
NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer |
200,000 | $0 | 200,000 (Direct) |
View |
| 2024-10-09 Gift |
2024-10-11 5:01 pm |
2022-12-22 2027-11-23 |
NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer |
15,000 | $11.5 | 85,000 (Direct) |
View |
| 2024-09-27 Exercise |
2024-10-01 5:23 pm |
N/A 2031-07-06 |
NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer |
45,000 | $0 | 168,073 (Direct) |
View |
| 2024-07-17 Option Award |
2024-07-19 4:31 pm |
N/A 2034-07-17 |
NewAmsterdam Pharma Co N.V. | NAMS | McKenna Mark C. Director |
72,500 | $0 | 72,500 (Direct) |
View |
Ownership |
2024-05-03 4:15 pm |
N/A 2033-08-14 |
NewAmsterdam Pharma Co N.V. | NAMS | JONES WILLIAM A JR Chief Commercial Officer |
0 | $0 | 945,598 (Direct) |
View |
| 2024-04-01 Option Award |
2024-04-02 4:30 pm |
N/A 2034-04-01 |
NewAmsterdam Pharma Co N.V. | NAMS | Audet Juliette Berangere Chief Business Officer |
250,000 | $0 | 250,000 (Direct) |
View |
| 2024-03-26 Exercise |
2024-03-27 4:30 pm |
N/A 2031-07-06 |
NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer |
201,673 | $0 | 970,229 (Indirect) |
View |
| 2024-03-26 Tax Withholding |
2024-03-27 4:30 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer |
11,197 | $22.72 | 970,229 (Indirect) |
View |
Ownership(A) |
2024-01-25 5:00 pm |
2022-12-22 2027-11-23 |
NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer |
0 | $0 | 100,000 (Direct) |
View |
Ownership(A) |
2024-01-25 5:00 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director |
0 | $0 | 234,683 (Direct) |
View |
| 2024-01-04 Option Award |
2024-01-08 7:43 pm |
N/A 2034-01-04 |
NewAmsterdam Pharma Co N.V. | NAMS | Lewis William Director |
100,000 | $0 | 100,000 (Direct) |
View |
| 2024-01-01 Option Award |
2024-01-03 5:26 pm |
N/A 2034-01-01 |
NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer |
150,494 | $0 | 150,494 (Direct) |
View |
| 2024-01-01 Option Award |
2024-01-03 5:21 pm |
N/A 2034-01-01 |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
323,771 | $0 | 323,771 (Direct) |
View |
| 2024-01-01 Option Award |
2024-01-03 5:19 pm |
N/A 2034-01-01 |
NewAmsterdam Pharma Co N.V. | NAMS | van der Kamp Hilde Johanna Director |
10,000 | $0 | 10,000 (Direct) |
View |
| 2024-01-01 Option Award |
2024-01-03 5:17 pm |
N/A 2034-01-01 |
NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director |
10,000 | $0 | 10,000 (Direct) |
View |
| 2024-01-01 Option Award |
2024-01-03 5:17 pm |
N/A 2034-01-01 |
NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer |
500,000 | $0 | 500,000 (Direct) |
View |
| 2024-01-01 Option Award |
2024-01-03 5:14 pm |
N/A 2034-01-01 |
NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer |
1,039,939 | $0 | 1,039,939 (Direct) |
View |
| 2024-01-01 Option Award |
2024-01-03 5:13 pm |
N/A 2034-01-01 |
NewAmsterdam Pharma Co N.V. | NAMS | Smither John W Director |
10,000 | $0 | 10,000 (Direct) |
View |